Mankind Pharma
add_icon

Mankind Pharma

2,124.30
+7.10
(0.34%)
Market Cap
87,692.18 Cr
PE Ratio
49.29
Volume
5,34,187.00
Day High - Low
2,134.90 - 2,087.00
52W High-Low
2,754.70 - 2,090.00
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
87,692.18 Cr
EPS
49.28
PE Ratio
49.29
PB Ratio
5.72
Book Value
370.30
EBITDA
3,554.70
Dividend Yield
0.00 %
Industry
Healthcare
Return on Equity
13.77
Debt to Equity
0.37
Analyst Rating and Forecast
- By Refinitiv from16 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+68.75 %
+68.75 %
Hold
Hold+18.75 %
+18.75 %
Sell
Sell+12.50 %
+12.50 %
Forecast For
Actual

Company News

View All News
Caret
neutral
Mankind Pharma announces investor conference call scheduled for February 3, 2026 at 6:00 PM IST to discuss Q3 & 9M FY26 financial results. Senior management including Vice Chairman Rajeev Juneja will participate.
neutral
Mankind Pharma witnessed a significant block trade on NSE worth ₹22.27 crores involving approximately 100,092 shares at ₹2,225.10 per share, indicating substantial institutional activity.
neutral
Mankind Pharma has announced that its board will convene on February 3 to consider and approve the company's third quarter financial results for the current fiscal year.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,613.80
#1 3,87,204.68
38.30
#1 54,729.00
9.71
#1 10,980
2.89
26.52
6,013.00
1,59,626.26
65.60
9,712.00
18.67
2,191
35.10
29.62
3,976.80
1,34,592.98
64.70
11,539.40
6.99
1,911
30.46
56.71
1,378.40
1,11,343.26
20.68
28,409.50
7.12
5,291
3.71
23.28
2,168.30
99,047.69
22.89
22,909.50
13.74
3,306
#1 72.75
57.69
1,166.70
97,376.32
#1 16.97
33,741.20
16.73
5,725
-0.38
23.20
873.40
87,884.48
17.63
23,511.00
18.55
4,615
34.60
34.17
2,124.30
#8 87,692.18
#8 49.29
#8 12,744.20
#1 20.90
#9 2,007
#10 -21.05
40.97
5,720.50
68,397.16
28.48
13,458.30
3.70
2,216
10.98
52.47
1,141.70
66,310.12
19.82
32,345.60
9.43
3,484
3.81
35.55
Growth Rate
Revenue Growth
20.90 %
Net Income Growth
3.39 %
Cash Flow Change
12.12 %
ROE
-32.07 %
ROCE
-46.01 %
EBITDA Margin (Avg.)
5.21 %

Quarterly Financial Results

Quarterly Financials
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Revenue
1,764
2,200
2,457
2,130
2,103
2,642
2,772
2,682
2,517
2,976
3,173
3,286
3,333
3,653
3,791
Expenses
1,441
1,724
1,835
1,654
1,636
1,924
2,025
2,000
1,836
2,196
2,217
2,383
2,401
2,724
2,776
EBITDA
323
476
622
477
467
718
746
681
681
780
956
903
933
930
1,016
Operating Profit %
17 %
21 %
24 %
21 %
20 %
25 %
25 %
23 %
24 %
23 %
28 %
26 %
22 %
24 %
25 %
Depreciation
47
78
79
85
85
87
97
110
100
103
101
187
231
219
222
Interest
13
16
10
13
5
6
9
9
9
11
7
221
191
171
170
Profit Before Tax
263
382
533
379
377
625
641
562
572
666
849
495
511
541
624
Tax
70
84
110
83
84
130
130
103
95
123
190
111
86
96
104
Net Profit
193
298
423
296
294
494
511
460
477
543
659
385
425
445
520
EPS in ₹
4.74
7.30
10.48
7.09
7.13
12.15
12.51
11.33
11.76
13.39
16.31
9.46
10.19
10.62
12.39

Balance Sheet

Balance Sheet
2021
2022
2023
2024
2025
Total Assets
6,373
9,148
9,715
11,963
27,760
Fixed Assets
1,664
3,588
4,251
4,545
19,005
Current Assets
3,907
4,407
4,328
6,568
6,988
Capital Work in Progress
372
702
550
282
826
Investments
1,512
1,110
1,346
2,568
2,042
Other Assets
2,824
3,749
3,568
4,568
5,887
Total Liabilities
6,373
9,148
9,715
11,963
27,760
Current Liabilities
1,353
2,624
1,863
2,120
5,664
Non Current Liabilities
156
208
229
268
7,528
Total Equity
4,863
6,316
7,623
9,576
14,568
Reserve & Surplus
4,682
6,115
7,395
9,323
14,291
Share Capital
40
40
40
40
41

Cash Flow

Cash Flow
2020
2021
2022
2023
2024
2025
Net Cash Flow
103
-92
156
22
77
22
Investing Activities
-436
-1,222
-1,369
-1,052
-2,081
-12,624
Operating Activities
1,070
1,137
920
1,813
2,152
2,413
Financing Activities
-531
-8
605
-740
5
10,233

Share Holding

% Holding
Sept 2022
Mar 2023
May 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
79.00 %
76.50 %
76.50 %
76.50 %
76.50 %
76.50 %
74.88 %
74.87 %
74.87 %
72.71 %
72.70 %
72.68 %
72.67 %
72.66 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
9.87 %
11.58 %
12.37 %
13.34 %
12.92 %
13.07 %
12.84 %
11.34 %
DIIs
0.00 %
2.64 %
2.64 %
4.64 %
4.39 %
9.49 %
11.14 %
9.95 %
9.90 %
11.06 %
11.48 %
11.50 %
11.92 %
13.25 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
4.15 %
4.15 %
1.02 %
1.11 %
1.14 %
1.22 %
1.46 %
1.55 %
1.60 %
1.64 %
1.52 %
1.36 %
1.52 %
Others
21.00 %
16.71 %
16.71 %
17.83 %
18.00 %
12.87 %
2.89 %
2.15 %
1.31 %
1.30 %
1.26 %
1.23 %
1.21 %
1.23 %
No of Share Holders
17
4,02,322
4,02,322
1,31,918
1,34,731
1,27,449
1,35,116
1,53,450
1,63,854
1,72,431
1,80,597
1,79,549
1,70,347
1,77,539

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
03 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
03 Feb 2026 2,256.70 2,117.85
09 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
09 Aug 2024 2,114.50 2,068.60
05 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Nov 2024 2,506.95 2,734.95
23 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
23 Jan 2025 2,738.25 2,515.05
21 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
21 May 2025 2,430.05 2,550.70
31 Jul 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jul 2025 2,578.00 2,575.00
07 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
07 Aug 2025 2,386.35 2,553.25
08 Aug 2025 DIVIDEND Dividend
₹ 1.00 /share
08 Aug 2025 2,575.00 2,541.90
06 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
06 Nov 2025 2,431.65 2,369.35

Announcements

Announcement under Regulation 30 (LODR)-Credit Rating4 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation4 days ago
Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results Of The CompanyJan 09, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 05, 2026
Closure of Trading WindowDec 24, 2025
Closure of Trading WindowDec 24, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Dec 10, 2025
Intimation Regarding ESG RatingDec 10, 2025
Intimation Regarding ESG RatingNov 28, 2025
Announcement under Regulation 30 (LODR)-AllotmentNov 26, 2025
Intimation Under Regulation 30 Of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015Nov 16, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Nov 15, 2025
Announcement under Regulation 30 (LODR)-Credit RatingNov 13, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 13, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 11, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Financial Results For The Quarter And Half Year Ended 30Th September 2025Nov 06, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 06, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationNov 06, 2025
Board Meeting Outcome for Outcome Of Board MeetingNov 06, 2025
Intimation Regarding ESG RatingNov 04, 2025
Intimation Regarding ESG RatingOct 29, 2025
Announcement under Regulation 30 (LODR)-Credit RatingOct 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 29, 2025
Board Meeting Intimation for Approval Of Financial Results For The Quarter And Half Year Ended On September 30 2025Oct 27, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionOct 10, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 04, 2025
Closure of Trading WindowSep 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 15, 2025
Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 10, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 09, 2025
Intimation Of Receipt Of Approval For ReclassificationSep 02, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 27, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSAug 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 25, 2025
Intimation Regarding ESG RatingAug 22, 2025
Announcement under Regulation 30 (LODR)-Updates on AcquisitionAug 19, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 11, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementAug 08, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 08, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMAug 07, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 06, 2025
Intimation For Submission Of Application For ReclassificationAug 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 01, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 01, 2025
Announcement Under Regulation 30- TDS Communication To The Shareholders.Jul 31, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportJul 31, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 31, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Tata Mid Cap Direct Plan-Growth
2.00%
500000
2.00%
2.00%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
6.44%
447252
1.40%
3.65%
Tata Balanced Advantage Fund Direct - Growth
0.56%
247500
0.56%
0.56%
Tata Arbitrage Fund Direct - Growth
0.00%
-242100
-0.27%
0.00%
Bandhan Large & Mid Cap Fund Direct-Growth
1.48%
230301
0.27%
0.60%
Invesco India Flexi Cap Fund Direct - Growth
0.00%
-224258
-1.08%
-1.22%
Bandhan Flexi Cap Fund Direct-Growth
0.63%
220000
0.63%
0.63%
Nippon India Large Cap Fund Direct-Growth
0.64%
193910
0.07%
0.64%
Nippon India Flexi Cap Fund Direct - Growth
1.58%
160000
0.35%
0.26%
Sundaram Large Cap Fund Direct - Growth
1.04%
159406
1.04%
1.04%
WhiteOak Capital Mid Cap Fund Direct - Growth
1.32%
159125
0.76%
0.80%
Franklin India Opportunities Direct Fund-Growth
1.20%
138115
0.33%
0.07%
PGIM India Midcap Fund Direct-Growth
2.02%
113400
0.22%
0.12%
ICICI Prudential Innovation Fund Direct - Growth
2.48%
95000
0.22%
2.48%
Aditya Birla Sun Life Large & Mid Cap Fund Direct -Growth
1.31%
83475
0.30%
0.25%
Mirae Asset Arbitrage Fund Direct - Growth
0.00%
-83475
-0.49%
-0.18%
Baroda BNP Paribas Midcap Fund Direct-Growth
0.75%
78927
0.75%
0.75%
HDFC Large Cap Fund Direct-Growth
1.48%
75000
0.00%
-0.06%
Bandhan Multi Asset Allocation Fund Direct-Growth
0.57%
70000
0.57%
0.57%
Nippon India Arbitrage Fund Direct-Growth
0.07%
-63225
-0.09%
0.04%
Canara Robeco Mid Cap Fund Direct - Growth
0.00%
-61931
-0.35%
-1.24%
Invesco India Manufacturing Fund Direct-Growth
0.00%
-61655
-1.91%
-1.94%
SBI Arbitrage Opportunities Fund Direct-Growth
0.12%
55125
0.03%
0.10%
DSP Dynamic Asset Allocation Fund Direct-Growth
0.95%
50297
0.28%
0.23%
ICICI Prudential Equity Arbitrage Direct-Growth
0.12%
-48825
-0.04%
0.08%

Technical Indicators

RSI(14)
Neutral
40.03
ATR(14)
Volatile
53.52
STOCH(9,6)
Neutral
28.25
STOCH RSI(14)
Neutral
25.50
MACD(12,26)
Bearish
-4.05
ADX(14)
Weak Trend
17.46
UO(9)
Bearish
41.08
ROC(12)
Downtrend And Accelerating
-3.61
WillR(14)
Oversold
-96.77

About Mankind Pharma

Mankind Pharma Limited is an Indian pharmaceutical company incorporated in 1991. It develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. The company operates in various therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory. Mankind Pharma entered the consumer healthcare segment in 2007 and has since...more
Listing Date
09 May, 2023(2 Years, 43 days)
Chairperson NameRAMESH CHAND JUNEJA